tiprankstipranks
Jefferies Reaffirms Their Buy Rating on EDAP TMS (EDAP)
Blurbs

Jefferies Reaffirms Their Buy Rating on EDAP TMS (EDAP)

In a report released yesterday, Michael Sarcone from Jefferies reiterated a Buy rating on EDAP TMS (EDAPResearch Report), with a price target of $14.00. The company’s shares closed yesterday at $10.60.

According to TipRanks, Sarcone is a 3-star analyst with an average return of 22.9% and an 83.33% success rate. Sarcone covers the Healthcare sector, focusing on stocks such as AxoGen, EDAP TMS, and Penumbra.

EDAP TMS has an analyst consensus of Strong Buy, with a price target consensus of $14.67, implying a 38.40% upside from current levels. In a report released on April 13, H.C. Wainwright also maintained a Buy rating on the stock with a $16.00 price target.

See today’s best-performing stocks on TipRanks >>

EDAP market cap is currently $391.4M and has a P/E ratio of -137.48.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Read More on EDAP:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles